Core C provides molecular assays for identifying, tracking, and quantifying cellular clones within complex multi-clonal mixtures. This function is designed to support basic stem cell biology, stem cell transplantation, and gene therapy research within the CCEH research base, but also among a broader community of basic and clinical scientists, at the FHCRC, UW, and other institutions. Services provided include VNTR analysis (Variable Number Tandem Repeat), to track the level of donor contribution in a transplant setting and LAM-PCR (Linear Amplification-Mediated PCR) to identify and track specific clones of cells in a chimeric mixture. Techniques are in place to estimate the level of gene transfer into stem cells, to estimate the number of stem cells engrafting, to detect the recruitment and exhaustion of individual stem cell clones, to identify leukemic outgrowth, and to determine insertion site specificity of retroviral vectors. A third assay category. Allele Tracking, has been added more recently to assist in the validation of transgenic and knockout mice developed by our users. To this end, we have developed nine multiplex PCR assays to quickly track the genotypes of several conditional knockout lines. Additional assays are developed a needed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK056465-14
Application #
8566004
Study Section
Special Emphasis Panel (ZDK1-GRB-G (O3))
Project Start
1999-09-15
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
14
Fiscal Year
2012
Total Cost
$147,405
Indirect Cost
$61,976
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Venkataraman, G M; Kennedy, L J; Little, M-T E et al. (2017) Thirteen novel canine dog leukocyte antigen-88 alleles identified by sequence-based typing. HLA 90:165-170
Hay, Kevin A; Hanafi, Laïla-Aïcha; Li, Daniel et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295-2306
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020
Burwick, Nicholas; Zhang, Michael Y; de la Puente, Pilar et al. (2017) The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res 55:23-32
Gust, Juliane; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 7:1404-1419
Aranda-Orgilles, Beatriz; Saldaña-Meyer, Ricardo; Wang, Eric et al. (2016) MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis. Cell Stem Cell 19:784-799
Laszlo, George S; Harrington, Kimberly H; Gudgeon, Chelsea J et al. (2016) Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget 7:43281-43294
Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173
Yeung, Cecilia C S; Deeg, H Joachim; Pritchard, Colin et al. (2016) Jumping translocations in myelodysplastic syndromes. Cancer Genet 209:395-402
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19

Showing the most recent 10 out of 259 publications